文献速递膀胱癌与上尿路尿路上皮癌

根治性放化疗治疗肌层浸润性膀胱癌中免疫细胞浸润的预后意义:RTOG 0524和RTOG 0712的二次分析

Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712.
PubMed 文献 · Eur Urol Oncol · 2024-04-18

该研究利用新型转录组图谱panel,对来自NRG/RTOG 0524和0712前瞻性试验的70例肌层浸润性膀胱癌(MIBC)治疗前肿瘤样本进行分析,验证放化疗(CRT)的预后免疫生物标志物。高免疫细胞含量聚类与较长无病生存(DFS)和总生存(OS)相关,T细胞浸润基因(CD8A和ICOS)及IDO1高表达也与较长DFS和OS相关。

要点

  • 高免疫细胞含量聚类与较低免疫细胞含量聚类相比,DFS的HR为0.53(95%CI 0.26-1.10;p=0.071),OS的HR为0.48(95%CI 0.24-0.97;p=0.040)。
  • T细胞浸润基因(CD8A和ICOS)高表达与较长DFS(HR 0.40,95%CI 0.21-0.75;p=0.005)和OS(HR 0.49,95%CI 0.25-0.94;p=0.033)相关。
  • IDO1(IFNγ特征)高表达与较长DFS(HR 0.44,95%CI 0.24-0.88;p=0.021)和OS(HR 0.49,95%CI 0.24-0.99;p=0.048)相关。

核心结论

  • 高免疫细胞含量及免疫激活相关基因(CD8A、ICOS、IDO1)高表达与接受放化疗的肌层浸润性膀胱癌患者较长的无病生存和总生存相关。
  • 这些发现应在纳入生物标志物的前瞻性放化疗试验中验证,尤其是纳入免疫治疗用于肌层浸润性膀胱癌的试验。

研究设计与样本

  • 对NRG/RTOG 0524和RTOG 0712前瞻性试验中70例肌层浸润性膀胱癌患者治疗前肿瘤样本进行二次分析。
  • 使用新型转录组图谱panel评估免疫细胞浸润,通过Kaplan-Meier法估计无病生存和总生存,并按与免疫细胞激活相关的基因进行分层。
  • 采用Cox比例风险模型评估组间差异。

主要发现

  • 基因表达谱聚类显示,高免疫细胞含量聚类与较低免疫细胞含量聚类相比,无病生存的HR为0.53(95%CI 0.26-1.10;p=0.071),总生存的HR为0.48(95%CI 0.24-0.97;p=0.040)。
  • T细胞浸润基因(CD8A和ICOS)高表达与较长无病生存(HR 0.40,95%CI 0.21-0.75;p=0.005)和总生存(HR 0.49,95%CI 0.25-0.94;p=0.033)相关。
  • IDO1(IFNγ特征)高表达与较长无病生存(HR 0.44,95%CI 0.24-0.88;p=0.021)和总生存(HR 0.49,95%CI 0.24-0.99;p=0.048)相关。

关键数值与推荐

  • 高免疫细胞含量聚类 vs 低免疫细胞含量聚类:无病生存HR 0.53(95%CI 0.26-1.10;p=0.071),总生存HR 0.48(95%CI 0.24-0.97;p=0.040)。
  • CD8A和ICOS高表达:无病生存HR 0.40(95%CI 0.21-0.75;p=0.005),总生存HR 0.49(95%CI 0.25-0.94;p=0.033)。
  • IDO1高表达:无病生存HR 0.44(95%CI 0.24-0.88;p=0.021),总生存HR 0.49(95%CI 0.24-0.99;p=0.048)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemoradiation therapy (CRT) is a treatment for muscle-invasive bladder cancer (MIBC). Using a novel transcriptomic profiling panel, we validated prognostic immune biomarkers to CRT using 70 pretreatment tumor samples from prospective trials of MIBC (NRG/RTOG 0524 and 0712). Disease-free survival (DFS) and overall survival (OS) were estimated via the Kaplan-Meier method and stratified by genes correlated with immune cell activation. Cox proportional-hazards models were used to assess group differences. Clustering of gene expression profiles revealed that the cluster with high immune cell content was associated with longer DFS (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.26-1.10; p = 0.071) and OS (HR 0.48, 95% CI 0.24-0.97; p = 0.040) than the cluster with low immune cell content. Higher expression of T-cell infiltration genes (CD8A and ICOS) was associated with longer DFS (HR 0.40, 95% CI 0.21-0.75; p = 0.005) and OS (HR 0.49, 95% CI 0.25-0.94; p = 0.033). Higher IDO1 expression (IFNγ signature) was also associated with longer DFS (HR 0.44, 95% CI 0.24-0.88; p = 0.021) and OS (HR 0.49, 95% CI 0.24-0.99; p = 0.048). These findings should be validated in prospective CRT trials that include biomarkers, particularly for trials incorporating immunotherapy for MIBC. PATIENT SUMMARY: We analyzed patient samples from two clinical trials (NRG/RTOG 0524 and 0712) of chemoradiation for muscle-invasive bladder cancer using a novel method to assess immune cells in the tumor microenvironment. Higher expression of genes associated with immune activation and high overall immune-cell content were associated with better disease-free survival and overall survival for patients treated with chemoradiation.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Rana Z, Kamran SC, Shetty AC, et al. Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712. Eur Urol Oncol. 2024. PMID: 38641541. doi:10.1016/j.euo.2024.03.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。